Young Whang, MD, PhD

Genitourinary medical oncologist at UNC Lineberger Cancer Center, husband of @SarahRoMD, father, person of faith, Tar Heel fan

[Ted Yanagihara, MD, PhD @tedradonc]

For med students applying to #RadOnc for the #Residency #Match2026. If you're still writing your personal statement, I dug up some old notes for you. 👇

Rad Onc @UNC_Lineberger is looking forward to meeting this year's class!

[Young Whang, MD, PhD @young_whang]

Two-thirds of doctors use OpenEvidence. Comprehensive article on benefits and risks. Downsides include incomplete answers, lack of studies on impact on pt care, loss of critical thinking skills. Despite drawbacks, the genie is out of bottle. https://t.co/eRbSS1GH3J

[William Y. Kim @WilliamKimMD]

why would time of day🔗w ICI response? Just a thought... Recall cortisol levels peak in AM & much lower in PM (diurnal variation). PD1 blockade activates TCR signaling hrs after infusion (so AM infusion = PM TCR activation while cort ⬇️. PM infusion viceversa...🤔

[Toni Choueiri, MD @DrChoueiri]

BRCAAway phase 2 (1L HRR-altered mCRPC):

Abi/pred + olaparib achieved longer OS
mOS 68 vs 28 mo vs Abi/pred (HR 0.39).

OS vs olaparib alone favored combo but CI crossed 1 (HR 0.51).

Continues the PARPi alone vs ARPI+PARPi discussion.

#GU26 #ProstateCancer

[Edwin Posadas, MD @EdwinPosadasMD]

Dual masking T-cell engagers do sounds VERY interesting #GU26.

[Katy Beckermann @katy_beckermann]

🧬 Early but very intriguing signal in heavily pretreated mCRPC.

VIR-5500 (AMX-500) is a dual-masked, PSMA-targeted T-cell engager designed to activate in the tumor microenvironment, with the goal of improving the therapeutic window.

📊 Phase 1 dose-escalation highlights:
51 patients treated ~95% post-taxane
No dose-limiting toxicities
CRS mostly grade 1–2

At ≥3000 µg/kg Q3W:
PSA50: 91%
PSA90: 55%
ORR: 67% in RECIST-evaluable patients (4/6)

Early evidence of durable PSA responses >1 year in select patients
PSMA-PET confirmed antitumor activity

👀 Community oncology implication: Still early, but this is exactly the kind of platform that could expand later-line options if safety and durability continue to hold in expansion cohorts.

#GU26 #ASCOGU26 #ProstateCancer #ClinicalTrials #OncologyTwitter

[Ravi A Madan M.D. @Dr_RaviMadan]

Dr. Johann De Bono presents a novel #PSMA x #CD3 bispecific

VIR-5500 #ProstateCancer #Immunotherapy

Very compelling early data with minimal toxicity.

Minor critique - not ideal that restating imaging is also the therapeutic target
@asco #GU26

[Young Whang, MD, PhD @young_whang]

In this relatively small trial with 20 per arm, there is a definitive OS advantage with the combination of olaparib/abiraterone with HR of 0.39. Spectacular result. Unfortunately, the application may be limited nowadays as most patients will have seen ARPI in the HSPC setting.

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#16 @ASCO #GU26 by #MahaHussain👉https://t.co/VAHaFneN3M👉BRCAAway Ph2 trial in 1L mCRPC w/ BRCA1/2 or ATM alterations #prostatecancer👉improved OS (68 mo) w/ abi + olaparib vs each monotherapy or sequential use👉supports upfront PARPi+ARPI👇@OncoAlert @urotoday @PCF_Science

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#16 @ASCO #GU26 by #MahaHussain👉https://t.co/VAHaFneN3M👉BRCAAway Ph2 trial in 1L mCRPC w/ BRCA1/2 or ATM alterations #prostatecancer👉improved OS (68 mo) w/ abi + olaparib vs each monotherapy or sequential use👉supports upfront PARPi+ARPI👇@OncoAlert @urotoday @PCF_Science

[Young Whang, MD, PhD @young_whang]

@dr_coops @allisonoconn Interesting. It’s hardly practice changing data. It looks like this trial was halted early due to ethical concerns after STAMPEDE data showing the benefit of radiation to the prostate. I still believe that cytoreductive prostatectomy should not be offered.

[Young Whang, MD, PhD @young_whang]

@tobiasmbuettner @allisonoconn Not cytoreductive prostatectomy. There is a well-establish role of radiation to prostate in metastatic disease, especially in “low volume” disease.

[Young Whang, MD, PhD @young_whang]

@dr_coops @allisonoconn There is definitely a role for radiation to the prostate in metastatic prostate cancer but I don’t agree with the idea that cytoreductive portatectomy can be offered in metastatic prostate cancer, outside of clinical trial.

[Young Whang, MD, PhD @young_whang]

@dr_coops @allisonoconn Cytoreductive prostatectomy? Umm, no! Where is the randomized trial data to support this assertion?

[Young Whang, MD, PhD @young_whang]

https://t.co/UM7YKC6suF NC attracted more new residents than any other state, bypassing Texas and Florida in previous years. The state's growth is attributed to good jobs in banking and tech, the topographical diversity and having smaller big-cities than Florida and Texas.

[Sarah Ro, MD @SarahRoMD]

The enormous amount of UPF consumed by children/teens is causing serious harm in the STROKE BELT. "Pharmacotherapy alone" approach is NOT the answer! Here is our latest paper on a strategy to reduce UPF/SSB consumption: https://t.co/PnMfsNKdr9

[Sarah Ro, MD @SarahRoMD]

This OMA podcast explores how our food environment is affecting the health of our children. Dr. V. Sushma Chamarthi, MD, FAAP, DABOM & I unpack our latest article, "The Impact of Ultra-Processed Foods on Pediatric Health" hosted by Dr. Suzanne Cuda.https://t.co/vwPDUgvC2A

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🔹NEW meta-analysis in mHSPC🔹
📊 Comparative Survival by Volume & Timing of Metastasis
👉 https://t.co/e6JIqQUsU1

🧩 Based on 11 phase III trials, this living NMA shows:
✅ Triplet therapy (ARPI + Docetaxel + ADT) yields the greatest OS benefit only in synchronous high-volume disease.
⚖️ For all other subgroups, ARPI + ADT alone remains the most effective and balanced approach.
🚫 Adding Docetaxel offers no additional benefit when ARPI is used
@PrafulRavi1 @Parminder1699 @neerajaiims @amerseburger @AarmstrongDuke
@BertrandTOMBAL @KarimFizazi @AlanBryce9

@OncoAlert
@Silke_Gillessen @AOmlin

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

https://t.co/Nkl7kR4zHq

This living network meta-analysis of 11 phase 3 trials shows that treatment benefits in metastatic hormone-sensitive #ProstateCancer differ by disease volume and timing. Triplet therapy (ARPI + docetaxel + ADT) offers the greatest survival advantage only in patients with synchronous high-volume disease. For all other subgroups—synchronous low-volume, metachronous high-volume, and metachronous low-volume—ARPI + ADT alone is the preferred option and outperforms ADT alone or docetaxel + ADT, with no clear added benefit from adding docetaxel when ARPIs are available.

Irbaz Bin Riaz
@PrafulRavi1
@Parminder1699
@neerajaiims
@amerseburger
@AarmstrongDuke
@BertrandTOMBAL
Karim Fizazi
@AlanBryce9

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@nataliagandur

[Arun Azad @AzadOncology]

1/ 🚨 Pleased to share that our latest manuscript is out now in @EUplatinum!

Baseline and on-treatment #ctDNA biomarkers in men with advanced #ProstateCancer treated with #LuPSMA.

https://t.co/koAm8SgnK9

Thanks to @LouiseKostos Heidi Fettke @PeterMacCC

[Young Whang, MD, PhD @young_whang]

@jgong15 Exactly. The superiority of Pluvicto in first-line CRPC, compared to active control like docetaxel has not been proven. The benefit of Pluvicto in mHSPC as triple therapy seems rather modest. Not only toxicity, but the cost to pt and to the system is probably unsustainable.

[Young Whang, MD, PhD @young_whang]

In the PSMAFore study (comparable population?), post-ARPI, OS on Pluvicto was 24 mo vs ARPI switch being 23 mo (not significant). OS in this study is 14 mo vs 18 mo, much shorter than ARPI switch in PSMAFore. Initial outcome between Pluv vs docetaxel comparable.

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science